TMCnet News
www.Xtremepicks.com: www.Xtremepicks.Com: Xtremepicks.Com Alerts For Wednesday, July 1, 2009 : PLCM, CYNO, SWKS, DCGN, And FSP(M2 PressWIRE Via Acquire Media NewsEdge) Xtremepicks.com Alerts for Wednesday include Polycom, Inc. (NASDAQ: PLCM), Cynosure, Inc. (Nasdaq: CYNO), Skyworks Solutions, Inc. (NASDAQ:SWKS), deCODE genetics (Nasdaq:DCGN), and Franklin Street Properties Corp. (Amex: FSP) --- Polycom, Inc. (NASDAQ: PLCM) opened Wednesday at $20.52 per share on trading volume of 555,181 shares. In a press release out on Jul 01, 2009 -- Polycom, Inc. (NASDAQ: PLCM), the global leader in telepresence, video and voice communications solutions, today announced that 28-year technology industry and sales veteran Andrew M. Miller has joined Polycom as executive vice president, Global Field Operations. Miller is well known in the IP networking industry for his strategic vision, successful sales track record, and demonstrated ability to manage high performance teams to drive market share growth. About Polycom Polycom, Inc. (NASDAQ: PLCM) is the global leader in telepresence, video, and voice solutions and a visionary in communications that empower people to connect and collaborate everywhere. Please visit www.polycom.com for more information. --- Cynosure, Inc. (Nasdaq: CYNO) opened Wednesday at $8.41 per share on trading volume of 185,517 shares. In a press release out on July 1, 2009 -- Cynosure, Inc. (Nasdaq: CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced that it has signed a multi-year, funded cooperative agreement with Unilever Ltd. to develop and commercialize light-based devices targeting the home use personal care market. Financial terms of the agreement were not disclosed. About Cynosure, Inc. Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and pigmented lesions, rejuvenate the skin, liquefy and remove unwanted fat through laser lipolysis and temporarily reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, contact Cynosure at 800-886-2966, or visit www.cynosure.com. --- Skyworks Solutions, Inc. (NASDAQ:SWKS) opened Wednesday at $9.89 per share on trading volume of 2,090,000 shares. In a press release out on Jul 01, 2009 -- Skyworks Solutions, Inc. (NASDAQ:SWKS), an innovator of high reliability analog and mixed signal semiconductors enabling a broad range of end markets, today announced that it is partnering with several of the energy industry's top solution providers to meet the growing worldwide demand for smart water, gas and electric meter readers. These strategic partnerships are enabling Skyworks to develop and ramp low-cost solutions for remote meter reading applications and smart grid technologies. Smart grids deliver power and energy from suppliers to consumers using digital technology, reducing utility and consumer costs while increasing system reliability. Governments and utilities are actively promoting smart grids to address energy independence, global warming and emergency resilience issues. About Skyworks Skyworks Solutions, Inc. is an innovator of high reliability analog and mixed signal semiconductors. Leveraging core technologies, Skyworks offers diverse standard and custom linear products supporting automotive, broadband, cellular infrastructure, energy management, industrial, medical, military and mobile handset applications. The Company's portfolio includes amplifiers, attenuators, detectors, diodes, directional couplers, front-end modules, hybrids, infrastructure RF subsystems, mixers/demodulators, phase shifters, PLLs/synthesizers/VCOs, power dividers/combiners, receivers, switches and technical ceramics. Headquartered in Woburn, Mass., Skyworks is worldwide with engineering, manufacturing, sales and service facilities throughout Asia, Europe and North America. For more information, please visit Skyworks' Web site at: www.skyworksinc.com. --- deCODE genetics (Nasdaq:DCGN) opened Wednesday at $0.48 per share on trading volume of 5,620,000 shares. In a press release out on July 1, 2009 -- The largest study of the genetics of schizophrenia ever undertaken has revealed several new common single-letter variants in the sequence of the human genome (SNPs) linked to risk of the disease. The study, by a multinational consortium of scientists led by a team from deCODE genetics (Nasdaq:DCGN), analyzed the genomes of more than 50,000 patients and control participants from fourteen countries. It is published today in the online edition of Nature. About deCODE deCODE is a bio-pharmaceutical company developing drugs and DNA-based tests to improve the treatment, diagnosis and prevention of common diseases. Its lead therapeutic programs, which leverage the company's expertise in chemistry and structural biology, include DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway for the prevention of heart attack; and DG071 and a platform for other PDE4 modulators with therapeutic applications in Alzheimer's disease and other conditions. deCODE is a global leader in human genetics, and has identified key variations in the genome (SNPs) conferring increased risk of major public health challenges from cardiovascular disease to cancer. Based upon these discoveries deCODE has brought to market a growing range of DNA-based tests for gauging risk and empowering prevention of common diseases. Through its CLIA-registered laboratory, deCODE offers deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProstateCancer(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and deCODE BreastCancer, for the common forms of breast cancer. deCODE is delivering on the promise of the new genetics.SM Visit us on the web at http://www.decode.com; on our diagnostics site at http://www.decodediagnostics.com; for our pioneering personal genome analysis service and new focused disease scans, integrating the genetic variants included in these tests and those linked to another twenty common diseases, as well as for our new deCODEme Cardio(TM) and deCODEme Cancer(TM) scans, at http://www.decodeme.com; and on our blog at http://www.decodeyou.com. --- Franklin Street Properties Corp. (Amex: FSP) opened Wednesday at $13.37 per share on trading volume of 227,170 shares. In a press release out on Jul 01, 2009 -- Franklin Street Properties Corp. ("FSP", "our" or "we") (NYSE Amex: FSP), an investment firm specializing in real estate, announced today its acquisition on June 30, 2009 of an office building in Eden Prairie, Minnesota for a purchase price of approximately $22,570,000. Completed in 2006, the building contains approximately 153,028 square feet of rentable space and is 100% leased. Eden Prairie is located within the greater Minneapolis/St. Paul metropolitan area. FSP has managed suburban properties in the greater Minneapolis/St. Paul metropolitan area since 2004. About Franklin Street Properties Corp. Franklin Street Properties Corp., based in Wakefield, Massachusetts, is focused on achieving current income and long-term growth through investments in commercial properties. FSP operates in two business segments: real estate operations and investment banking/investment services. The majority of FSP's property portfolio is suburban office buildings, with select investments in certain central business district properties. FSP's subsidiary, FSP Investments LLC (member, FINRA and SIPC), is a real estate investment banking firm and a registered broker/dealer. FSP is a Maryland corporation that operates in a manner intended to qualify as a real estate investment trust (REIT) for federal income tax purposes. To learn more about FSP please visit our website at www.franklinstreetproperties.com. Xtremepicks.com profiles early stage microcap and growth stocks that provide innovative products or services resulting in potentially "hyper-growth" opportunities. Often, these companies have yet to be recognized by Wall Street and the undiscovered nature of Xtremepicks.com's profile companies provide our members the opportunity to learn about these companies at their development stage, and more importantly before they possibly "turn the corner" and get exposed to a much larger investing audience. Xtremepicks.com (www.Xtremepicks.com) has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by Xtremepicks.com to be accurate, and should not be considered to be all-inclusive. Xtremepicks.com is a leading information resource for evaluating investment opportunities in small and microcap stocks. We focus on a limited number of companies in order to provide comprehensive coverage, including unique investment related features not available anywhere else on the Internet. To feature a company or to get more information, please visit us at www.Xtremepicks.com or email us at [email protected] Xtremepicks.coms affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. Xtremepicks.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. To view full disclaimers, go to http://www.Xtremepicks.com/disclaimer.htm ((Comments on this story may be sent to [email protected])) (c) 2009 M2 COMMUNICATIONS |